Device Trial Radar · NCT05610267
Gentrix® Surgical Matrix for Soft Tissue Reinforcement in Ventral Hernia Repair
Last checked: Nov 20, 2026Latest source record: Jun 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Nov 22, 2022
Primary completion
Dec 28, 2022
Study completion Dec 28, 2022
Sponsor
- Lead sponsor
- Integra LifeSciences CorporationPublic (IART)
- Sponsor type
- Industry
- First posted
- Nov 9, 2022
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to collect additional safety data and demonstrate the performance of Integra Gentrix® Surgical Matrix for reinforcement of ventral hernia repairs.
Conditions
- Ventral Hernia
Interventions
Retrospective chart reviewDevice
The retrospective chart review will include the full consecutive series of patients between 22 years and 80 years old who underwent abdominal wall reconstruction for achart hernia with Integra Gentrix® Surgical Matrix during the time period between November 1, 2017, and present (90 days prior to the start of data collection).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Post-operative Complications Requiring Procedural Intervention Within 90 Days Post Index ProcedureTime frame: 90 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Surgical Healing Arts Center
Fort Myers, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.